Nivolumab Therapy for Synchronous ALK-Positive Lung Cancer and Gastric Cancer

Publisher： Karger

E-ISSN： 1662-6575|10|1|361-367

ISSN： 1662-6575

Source： Case Reports in Oncology, Vol.10, Iss.1, 2017-04, pp. : 361-367

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Drug‐induced reduction in estimated glomerular filtration rate in patients with ALK‐positive non‐small cell lung cancer treated with the ALK inhibitor crizotinib

By  

CANCER, Vol. 120, Iss. 5, 2014-03 ,pp. : 664-674

John Wiley & Sons Inc

Access to resources Recommend Favorite

ALK‐positive non–small cell lung cancer: Mechanisms of resistance and emerging treatment options

By  

CANCER, Vol. 120, Iss. 16, 2014-08 ,pp. : 2392-2402

John Wiley & Sons Inc

Access to resources Recommend Favorite

Detection of Anaplastic Lymphoma Kinase (ALK) Gene Rearrangement in Non-Small Cell Lung Cancer and Related Issues in ALK Inhibitor Therapy: A Literature Review

By Yi Eunhee S.  

Molecular Diagnosis & Therapy, Vol. 16, Iss. 3, 2012-06 ,pp. : 143-150

Adis International

Access to resources Recommend Favorite

Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer

By  

MUSCLE AND NERVE, Vol. 52, Iss. 2, 2015-08 ,pp. : 307-308

John Wiley & Sons Inc

Access to resources Recommend Favorite

Targeted therapy in gastric cancer

By  

APMIS (ELECTRONIC), Vol. 123, Iss. 5, 2015-05 ,pp. : 365-372

John Wiley & Sons Inc

Access to resources Recommend Favorite